Mankind Pharma Ltd

- No explicit mention of new fundraising through debt or equity in the current report. - The company is focused on strengthening its balance sheet and reducing net debt, which stood at INR5,784 crores as of March 31, 2025. - Debt repayments are targeted, aiming for an EBITDA to debt ratio of 1.1x to 1.2x by the end of FY '26. - The plan includes retiring the complete acquisition-related debt by FY '28. - Finance costs have decreased due to repayment of INR3,000 crores in commercial papers in January 2025. - Cash flow remains strong, supporting debt reduction rather than indicating new fundraising. - No mention of equity issuance or planned fundraise activities in the near future.

- FY '25 capex spend increased to INR 531 crores, which is 4.3% of total revenue, in line with the guidance of 4% to 5% of revenue. (Page 7) - The company continues R&D investments at approximately 2.5% to 3% of sales, aimed at building a strong portfolio and pipeline. (Page 11) - Strategic focus on restructuring and integrating acquired businesses (e.g., BSV and TTK Rx businesses) to drive operational efficiency and growth. (Pages 8-10) - No specific mention of large-scale new capital projects or future capex guidance beyond maintaining 4%-5% of revenue level for capex and continued R&D spend. - Emphasis on strengthening the foundation, portfolio optimization, and improving margins with ongoing investments in commercial excellence and talent upgradation. (Pages 9-14)

- Expectation to outperform Indian Pharmaceutical Market (IPM) by about 1.2x in domestic revenue growth for FY '26. - Chronic therapies projected to grow 1.2x to 1.3x the market, led by cardiac and anti-diabetic segments with consistent outperformance (1.5x and 1.3x IPM growth respectively). - Consumer healthcare business anticipated to sustain strong growth, supported by recent successful product launches and improved presence in modern trade and e-commerce. - BSV (super-specialty portfolio) expected to grow at 18% to 20% overall with international growth above 20%. - International business saw 37% organic growth in FY '25; continuing growth is expected. - Restructuring and integration efforts in acute segment expected to result in growth restarting from Q2 FY '26. - New product pipeline includes clinical trials for obesity and metabolic disorder drugs, signaling potential future product launches. - Overall revenue growth in FY '25 was 19% year-on-year, with optimism for continued strong performance ahead.

- Guidance for EBITDA margins is maintained at 25%-26% overall; consumer healthcare currently has lower EBITDA margins (~20%) but is expected to scale up to company average. - Adjusted EBITDA margin improved to 25.9% in FY '25 from 24.6% in FY '24; expected to remain in the 25%-26% range in FY '26. - Domestic revenue growth expected to outperform IPM by around 1.2x in FY '26. - Chronic therapy growth outperformed IPM chronic by 1.3x in Q4 FY25, indicating strong growth. - R&D investment to increase to 2.5%-3% of revenue in FY '26, up from 2.1% in FY '25, which may modestly affect margins but supports future growth. - Profit after tax for FY '25 increased marginally by 3.4%; PAT for Q4 decreased due to higher finance and depreciation costs related to acquisitions. - Target EBITDA to debt ratio of around 1.1x by end FY '26 with plans to retire acquisition-related debt by FY '28. - EPS growth expected aligned with revenue and margin growth, with cash EPS at INR 64.4 for FY '25.

The transcript does not explicitly mention any details regarding the current or expected order book or pending orders for Mankind Pharma. The discussion primarily covers financial performance, growth guidance, business integration, margins, therapy segment performance, product pipeline, and market strategies. There is no specific information on order book or pending orders available in the provided pages of the document.